Compare BON & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BON | LTRN |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 10.0M |
| IPO Year | 2020 | 2020 |
| Metric | BON | LTRN |
|---|---|---|
| Price | $1.05 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | 8.9K | ★ 166.9K |
| Earning Date | 09-23-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $385.87 | N/A |
| Revenue Next Year | $15.63 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $0.36 |
| 52 Week High | $1.94 | $4.34 |
| Indicator | BON | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 20.94 |
| Support Level | $0.97 | N/A |
| Resistance Level | $1.17 | $0.84 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 47.59 | 0.07 |
Bon Natural Life Ltd focuses on the manufacturing of personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements by its customers. It has developed four technology platforms for large-scale separation, safety improvement, activity enhancement, and functional compounding of natural products. The company's offerings include Fragrance compounds, Health supplements, and Bioactive food ingredients. The company generates revenue from the sale of its products, the majority derived from the sale of Fragrance compounds, which include natural compounds extracted from plants for cosmetic applications.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.